New Data Released on Long-Acting Hemophilia B Treatment

December 8, 2015

Note: The following is the edited version of a press release issued by CSL Behring. The original release can be found here. On December 7, 2015, CSL Behring presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.